Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Management
Management criteria checks 2/4
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's CEO is Da Jun Zhao, appointed in May 2023, has a tenure of 1.5 years. total yearly compensation is CN¥1.88M, comprised of 89.9% salary and 10.1% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth HK$109.15M. The average tenure of the management team and the board of directors is 1.5 years and 1.5 years respectively.
Key information
Da Jun Zhao
Chief executive officer
CN¥1.9m
Total compensation
| CEO salary percentage | 89.9% |
| CEO tenure | 1.5yrs |
| CEO ownership | 1.5% |
| Management average tenure | 1.5yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit
Nov 04
There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump
Oct 14Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders
May 06What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | CN¥105m |
| Jun 30 2024 | n/a | n/a | CN¥111m |
| Mar 31 2024 | n/a | n/a | CN¥102m |
| Dec 31 2023 | CN¥2m | CN¥2m | CN¥109m |
| Sep 30 2023 | n/a | n/a | CN¥191m |
| Jun 30 2023 | n/a | n/a | CN¥242m |
| Mar 31 2023 | n/a | n/a | CN¥142m |
| Dec 31 2022 | CN¥3m | CN¥2m | CN¥138m |
| Sep 30 2022 | n/a | n/a | CN¥132m |
| Jun 30 2022 | n/a | n/a | CN¥112m |
| Mar 31 2022 | n/a | n/a | CN¥213m |
| Dec 31 2021 | CN¥5m | CN¥2m | CN¥213m |
| Sep 30 2021 | n/a | n/a | CN¥198m |
| Jun 30 2021 | n/a | n/a | CN¥201m |
| Mar 31 2021 | n/a | n/a | CN¥188m |
| Dec 31 2020 | CN¥3m | CN¥1m | CN¥165m |
| Sep 30 2020 | n/a | n/a | CN¥191m |
| Jun 30 2020 | n/a | n/a | CN¥165m |
| Mar 31 2020 | n/a | n/a | CN¥204m |
| Dec 31 2019 | CN¥3m | CN¥1m | CN¥227m |
| Sep 30 2019 | n/a | n/a | CN¥151m |
| Jun 30 2019 | n/a | n/a | CN¥151m |
| Mar 31 2019 | n/a | n/a | CN¥91m |
| Dec 31 2018 | CN¥2m | CN¥1m | CN¥112m |
| Sep 30 2018 | n/a | n/a | CN¥95m |
| Jun 30 2018 | n/a | n/a | CN¥78m |
| Mar 31 2018 | n/a | n/a | CN¥77m |
| Dec 31 2017 | CN¥1m | CN¥1m | CN¥75m |
Compensation vs Market: Da Jun's total compensation ($USD260.15K) is below average for companies of similar size in the Hong Kong market ($USD478.62K).
Compensation vs Earnings: Da Jun's compensation has been consistent with company performance over the past year.
CEO
Da Jun Zhao (54 yo)
1.5yrs
Tenure
CN¥1,882,870
Compensation
Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.5yrs | CN¥1.88m | 1.51% HK$ 109.1m | |
| CFO, Deputy GM | 14.3yrs | CN¥1.18m | 0.20% HK$ 14.2m | |
| Co-Founder & Deputy GM | 28yrs | CN¥2.22m | 0.87% HK$ 63.0m | |
| Core Technical Personnel | no data | no data | 0.11% HK$ 8.2m | |
| Deputy General Manager | 1.5yrs | no data | 0.064% HK$ 4.6m | |
| Deputy General Manager | 1.5yrs | no data | 0.018% HK$ 1.3m | |
| Deputy General Manager | 1.5yrs | no data | 0.020% HK$ 1.5m |
1.5yrs
Average Tenure
53yo
Average Age
Experienced Management: 1349's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.8yrs | CN¥1.88m | 1.51% HK$ 109.1m | |
| CFO, Deputy GM | 1.5yrs | CN¥1.18m | 0.20% HK$ 14.2m | |
| Non-Executive Director | 11.5yrs | no data | no data | |
| Supervisor | 1.5yrs | no data | no data | |
| Non Executive Director | 12.4yrs | no data | no data | |
| Independent Chairman of Supervisory Board | 7.4yrs | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | CN¥116.67k | no data | |
| Independent Non-Executive Director | 1.5yrs | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | CN¥116.67k | no data | |
| Employee Representative Supervisor | 1.5yrs | no data | 0.0038% HK$ 272.3k |
1.5yrs
Average Tenure
54yo
Average Age
Experienced Board: 1349's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.